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PR1 is also processed and presented by NE, which may result in 
enhanced immunogenicity of the peptide conapared to peptides 
derived from a single protein. Redundancy of proteins may also 
lessen the impact of tumor loss variants after PRl-based 
immunotherapy. 
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TREATMENT OF DONORS WITH INTERLEUKIN-18 REDUCES ACUTE 
GRAFT-VERSUS-HOST DISEASE VIA STAT6 AND PRESERVES CD8 ÷ 
MEDIATED GRAFT-VERSUS-LEUKEMIA EFFECTS 
Reddy, p.t; Teshima, T.I; IJildebrandt, G J; ~(illiams, D.I; Liu, C?; 
Cooke, IvY; FeJv'ara, J.LJ 1. lnte~'nal Medicine, UMve1"sity of k/Iichi- 
gan Medical CeT~ter, Am7 A't'bor, MI; 2. Unive't'sity of Flo~'ida, 
GaineswTle, FL. 
haterleukin 18 modulates both Thl/Th2 responses and stimulates 
hcmatopoietic growth factor secretion. VVe investigated the effect of 
pretreating bone marrow transplant (BMT) donors with IL- 18 on the 
severity of acute GVHD using a well-characterized irradiated experi- 
mental BMT model (BALB/c(H-2d-~ B6 (H-2u). Pretreatment of 
allogeneic BMT donors with IL-18 (lpg/day of rmIL-18 for 10 days, 
day 11 to -1) significantly improved survival, and caused significant 
reduction in serum levels of TNF-c~(212 +18pgJml vs 524 +69pg/ml, 
P<0.05)and LPS (5.3 --1.1U/ml vs 12.4 _+l.3U/ml, P<0.05) and 
GVHD related intestinal histopathology (P<0.05). All surviving mice 
showed complete donor engTafunent, hus ruling out graft rejection 
and mixed chimerism as causes for decreased GVHD. IL-18 pretreat 
naent was also associated with reduced IFN- 7 (1987 -+387pg/ml vs 
4686 _+964p~ml, P<0.03) and greater IL-4 secretion (54.8 _+9.3pgkni 
vs 14.5 _+3.4pg/ml, P<0.04) by donor T cells after BMT. Surprisingly, 
when IFN-ydeficient 1nice were pretrcated with rmIL-18 and used as 
donors acute GVIID mortality was reduced thus ruling out the role 
of donor IFN-Tin this effect. Acute GVHD mortality was also 
reduced when IL-18 was administered to donors deficient in STAT4. 
Treannent of STAT6 deficient donors with IL-18 did not alter IFN- 
7 secretion (14.3 _+2.I ng/ml vs 10.2 _+3.8ng/mI, P=NS) or enhance 
IL-4 production. Furthermore pretreatment of STAT6-/ donors 
with IL-18 did not reduce acute GVHD mortality thus confirming 
the role of STAT6 signaling in IL-18's protective ffect. "eVe next 
investigated whether IL-18 can maintain a graft-versus-leukemia 
(GVL) effect using the same model and by injecting recipients with 
host-type (H-2 b) EL-4 MHC II-/-lymphoma cells at the time of 
BMT. IL-18 txeamlent did not alter donor CD8 + cytotoxic T lym 
phocyte (CTL) activity" and preserved graft versus leukemia (GVL) 
effects after allogeneic BMT (70% v I0%, P < 0.01). Our results 
demonstrate hat pretreatment of donors with IL-18 preserves the 
CD8 + mediated GVL effects but reduces acute GVHD in a donor 
derived IFN 3*independent but in a STAT6 dependent mechanism. 
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TACROLIMUS (FK-506) AND MYCOPHENOLATE MOFETIL (MMF) 
GVHD PROPHYLAXIS IN ALLOGENEIC SCT (ALLOSCT) RECIPIENTS: 
ALTERED MMF PHARMACOKINETICS (PK) ASSOCIATED WITH AGVHD 
BessT~es~:JTy, 0.; Ostmkwo, I.; Ha~v'ison, L.; Wolownik, K.; Wischhove'/', C.; 
Gatvin, ft.; Geo*ge, D.; Del Tovo, G.; Bradley, M.; Cairo, M.& CblTd'J'en's 
Hospital of New YoJ'k PT"esbyteHan, Columbia University, New York, NI( 
FK-506/NLMF is an effective salvage therapy for steroid-refrac- 
tory chronic (C) GVHD (Mookerjee t al, BMT 1999; 24:517-20) 
and has been used for prophylaxis of acute (A) and C GVHD fol 
lowing nonmyeloablative conditioning in adults (Rini BI et al, 
JCO 2002; 20:2017-203. We investigated safety and efficacy of 
FK-506/MMF regimen for GVHD prophylaxis to spare th use of 
methotrexate (MTX) and steroids in 29 pts (mean age 8.5 [range 
0.5-22 years]; 21 M, 8 F) undergoing 32 AlloSCT for hematologic 
malignancies (n=20), non-malignant disorders (n=7), and neurob- 
lastoma (n=2). GVHD prophylaxis included FK-506 0.03 
mg/kg/day continuous 1V on Day -1 or 1st day of conditioning 
plus MMF 15 mg/kg/dose PO/IV BID starting Day +1. Doses of 
FK-506 and MMF were adjusted to maintain concentrations with- 
in reference ranges of 5-20 ng/mL for FK-506 and 1-3.5 mcg/mL 
for mycophenoleic a id (MPA). HLA typing was serologic for A 
and B and high resolution DRB1. Stem cell sources were 6/6 
UCB (n=43, 5/6 UCB class I mismatch (n=4), 4/6 UCB (mismatch: 
class I [n=8], class II [n-l], double class I/II [n=3]), 6/6 related (R) 
BM (n=3), 6/6 RPBSCT (n=8), 5/6 RPBSCT class I mismatch 
(n=l). kanong 28 evaluable pts, mean days to ANC _>500/ram 3 x 2 
days was 14 (11-17) and 27 (8-70) following related RPBSCT/BM 
and UCB, respectively. Fifteen pts (53.6%) developed ->grade II
AGVHD: 7 RBM/PBSC and 8 UCB. The incidence of grade 
III/IV AGVHD was 32% (5 RBM/PBSC and 4 UCB) and 6% for 
CGVHD (n=2). FK-506/MMF was well tolerated, with 2 episodes 
of grade I I I - IV neurotoxicity (disorientation and leukoen- 
cephalopathy). M PA trough concentrations were monitored in the 
second half of the study (n=123. Eight pts developed AGVHD and 
7 bad MPA below target range (<1 mcg/ml) at GVHD onset. 
MMF doses >900 mg/m 2 IV/PO q6h (4 times standard ose) were 
required to achieve target MPA trough concentrations in the early 
AlloSCT period (< Day +30). Five of 12 pts monitored achieved 
target MPA levels before Day +30 and the incidence of >Grade III 
AGVHD was 20%. The estimated 1-year OS is 52.1%. These 
results uggest that FK506/MMF is a safe and effective MTX and 
steroid sparing GVHD prophylaxis regimen following R and 
UCB AlloSCT. Further pharmacokinetic and pharmacodynamic 
studies are ongoing in AlloSCT recipients to define the optimal 
dosing regimen of A~V[F. 
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CD83 ANTIGEN: A POTENTIAL NEW TARGET FOR GRAFT VERSUS 
HOST DISEASE PREVENTION 
Ml~7~steT; D.J.; Kato, J¥l.; 3/lacDo~ald, K.P., Rice, A.M.; Hart, D.N. 
Cance'r ]3iotheT~ap~, Mater Medical Researeh Institztte, Soath BvisbaTze, 
QLD, Aust1"alia. 
Novel strategies are required to overcome the limitations imposed 
on hematopoietic stem cell transplantation by graft versus host dis- 
ease (GVHD). Cm'rent GVHD therapies focus on elimination or 
attenuation f the effcctor T cell. There is emerging evidence in the 
literature to suggest a primary role for dendritic ells (DC) in the 
initiation of GVHD. CD83 is a marker of DC differentiation/activa- 
tion. Polyclonal anti-CD83 antibody (RA83) inhibits the T lympho- 
cyte proliferative response in the mkxed leukocyte reaction (MLR) 
stinmlated by allogeneic monocyte derived DC (MoDC). We inves- 
tigated the mechanism of tltis RA83 mediated immunosuppression 
and found that it was not due to functional blockade of CD83. It 
required the presence of NK-cclls, Fab fragments of RA83 did not 
inhibit the MLR, and treatment with an Fc7 receptor III (CD16) 
blocldng monoclonaI antibody (3G8) prevented the blockade, indi- 
cating that it was due to antibody dependent cellular cytotoxicity 
(ADCC) of CD83 + cells. In additional experiments we showed that 
activated NiL<ells lyse 5/~Cr labelled CD83 + MoDC in the presence 
of RA83, but not in the presence of non-immune polyclonal anti- 
body. hnmamre CD83 MoDC were not lysed in the presence of 
RA83. However, lysis of MoDC did not account for all the effect 
because stimulation with allogeneic MoDC fixed with paraformalde- 
hyde also exhibited inhibition of T lymphocyte proliferation i  the 
presence of RA83. This implied that CD83 + targets of ADCC must 
exist or arise in the responder cell preparation. YVe then established 
that activated blasting T<ells (CD25 +, Ki67 +) stimulated by allo- 
geneic MoDe also express CD83 and that they become targets of 
NK-cell mediated ADCC. Thus, CD83 is expressed by both stimu- 
lator and responder cells in the MLR. Simultaneous targeting of 
both activated cell populations by a single reagent such as anti- 
CD83 may be a potent means of achieving therapeutic imnmnosup- 
pression for allogeneic hematopoietic stem cell transplantation. 
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IMPROVED OUTCOME IN ACUTE LETHAL MURINE GRAFT VERSUS 
HOST DISEASE (GVHD) FOLLOWING ADMINISTRATION OF THE PRO- 
TEASOME INHIBITOR PS-341 
Webziak, L.AJ; &m, K.2; Sayevs, T.J.2; Mzlrpby, I4~J. l I. Microbiolo- 
gy, University of Nevada, Rent, Rent, NV; 2. SAIC-t;rederick, Freder- 
ick, 3lID. 
Proteasome inhibitors have recently shown much promise by 
selectively acting on various neoplastic ells, particularly" myelo- 
mas. We have recently found that the use of proteasome inhibi- 
tion with PS-34I sensitizes neoplastic ells to TRAIL mediated 
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